Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5940
    -0.0009 (-0.15%)
     
  • NZD/EUR

    0.5555
    +0.0014 (+0.26%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    84.02
    +0.45 (+0.54%)
     
  • GOLD

    2,345.20
    +2.70 (+0.12%)
     
  • NASDAQ

    17,729.06
    +298.55 (+1.71%)
     
  • FTSE

    8,145.21
    +66.35 (+0.82%)
     
  • Dow Jones

    38,232.75
    +146.95 (+0.39%)
     
  • DAX

    18,166.91
    +249.63 (+1.39%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.4810
    +0.9850 (+1.06%)
     

Novartis’s 1Q18 Estimates: Expectations for Alcon

Novartis’s 1Q18 Estimates: Expectations for Alcon

Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.